These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A study of the roles of some immunological biomarkers in the diagnosis of rheumatoid arthritis. Khudhair HAA J Med Life; 2023 Aug; 16(8):1194-1200. PubMed ID: 38024817 [TBL] [Abstract][Full Text] [Related]
6. [Immunological markers of rheumatoid arthritis]. Matuszewska A; Madej M; Wiland P Postepy Hig Med Dosw (Online); 2016 Mar; 70():251-7. PubMed ID: 27117100 [TBL] [Abstract][Full Text] [Related]
7. Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. Dhaon P; Das SK; Srivastava R; Dhakad U Int J Rheum Dis; 2018 Nov; 21(11):1933-1939. PubMed ID: 28608433 [TBL] [Abstract][Full Text] [Related]
8. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. del Val del Amo N; Ibanez Bosch R; Fito Manteca C; Gutierrez Polo R; Loza Cortina E Clin Exp Rheumatol; 2006; 24(3):281-6. PubMed ID: 16870095 [TBL] [Abstract][Full Text] [Related]
9. Early diagnostic and prognostic values of anti-cyclic citrullinated peptide antibody and cartilage oligomeric matrix protein in rheumatoid arthritis. Algergawy SA; Abd El-Sabour M; Osman AS; Emam SM; Elham N Egypt J Immunol; 2013; 20(2):11-20. PubMed ID: 24617043 [TBL] [Abstract][Full Text] [Related]
10. Unique correlation between mutated citrullinated vimentine IgG autoantibodies and markers of systemic inflammation in rheumatoid arthritis patients. Zahran WE; Mahmoud MI; Shalaby KA; Abbas MH Indian J Clin Biochem; 2013 Jul; 28(3):272-6. PubMed ID: 24426223 [TBL] [Abstract][Full Text] [Related]
11. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Berglin E; Johansson T; Sundin U; Jidell E; Wadell G; Hallmans G; Rantapää-Dahlqvist S Ann Rheum Dis; 2006 Apr; 65(4):453-8. PubMed ID: 16176994 [TBL] [Abstract][Full Text] [Related]
12. Application of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis in Korean patients with undifferentiated arthritis. Jung SJ; Kang Y; Ha YJ; Lee KH; Lee SW; Lee SK; Park YB Scand J Rheumatol; 2012 May; 41(3):192-5. PubMed ID: 22401568 [TBL] [Abstract][Full Text] [Related]
13. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Hambardzumyan K; Bolce R; Saevarsdottir S; Cruickshank SE; Sasso EH; Chernoff D; Forslind K; Petersson IF; Geborek P; van Vollenhoven RF Ann Rheum Dis; 2015 Jun; 74(6):1102-9. PubMed ID: 24812287 [TBL] [Abstract][Full Text] [Related]
14. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Greiner A; Plischke H; Kellner H; Gruber R Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545 [TBL] [Abstract][Full Text] [Related]
15. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946 [TBL] [Abstract][Full Text] [Related]
16. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis. Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044 [TBL] [Abstract][Full Text] [Related]
17. [Antibodies to citrullinated proteins in rheumatoid arthritis]. Matsui T Nihon Rinsho Meneki Gakkai Kaishi; 2006 Apr; 29(2):49-56. PubMed ID: 16651702 [TBL] [Abstract][Full Text] [Related]
18. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Lindqvist E; Eberhardt K; Bendtzen K; Heinegård D; Saxne T Ann Rheum Dis; 2005 Feb; 64(2):196-201. PubMed ID: 15458956 [TBL] [Abstract][Full Text] [Related]
19. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide. El-Barbary AM; Kassem EM; El-Sergany MA; Essa SA; Eltomey MA J Rheumatol; 2011 May; 38(5):828-34. PubMed ID: 21362765 [TBL] [Abstract][Full Text] [Related]
20. Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide Antibody, C-Reactive Protein, and Erythrocyte Sedimentation Rate for the Clinical Diagnosis of Rheumatoid Arthritis. Shen R; Ren X; Jing R; Shen X; Chen J; Ju S; Yang C Lab Med; 2015; 46(3):226-9. PubMed ID: 26199263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]